PDCD1 and colorectal carcinoma: For CRC, anti-programmed death 1 (anti-PD-1) antibodies, such as pembrolizumab and nivolumab, and CTLA-4 inhibitor ipilimumab were approved by FDA (Pan et al., 2021).